Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T. Lei, Michael T. Lewis, Lacey E. Dobrolecki et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 3
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J. Jaehnig, Meenakshi Anurag, Yongchao Dou et al.|Cell Reports Medicine|2025Cited by 3
Abstract PS4-02: Patient-derived Xenografts (PDX) Allow Deconvolution of Combination Chemotherapy ResponseJonathan T. Lei, Michael T. Lewis, Lacey E. Dobrolecki et al.|Clinical Cancer Research|2025Cited by 0
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersLisa A. Carey, Haoquan Zhao, Chang In Moon et al.|UNC Libraries|2025Cited by 0